Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2004 May 15;38 Suppl 4:S357-62.

Quinolone resistance among pneumococci: therapeutic and diagnostic implications.

Author information

  • 1Department of Microbiology, Toronto Medical Laboratories/Mount Sinai Hospital, University of Toronto, Toronto, Canada. dlow@mtsinai.on.ca

Abstract

Fluoroquinolones are widely recommended as empirical monotherapy for community-acquired pneumonia. Since 1999, case reports of failure of levofloxacin therapy due to levofloxacin-resistant strains of Streptococcus pneumoniae have started to appear. Most worrying is that, in some cases, levofloxacin resistance has been acquired by pneumococci within days of the initiation of therapy. Because use of current clinical antimicrobial resistance breakpoints fail to identify the majority of S. pneumoniae isolates with only first-step mutations, current treatment guidelines not only may have implications with regard to the ability of surveillance programs to detect emerging resistance but may have therapeutic implications as well.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk